HomeCompareSYNH vs EQR

SYNH vs EQR: Dividend Comparison 2026

SYNH yields 4.65% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $13.3K in total portfolio value
10 years
SYNH
SYNH
● Live price
4.65%
Share price
$42.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.1K
Annual income
$626.90
Full SYNH calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — SYNH vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNHEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYNH + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYNH pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYNH
Annual income on $10K today (after 15% tax)
$395.53/yr
After 10yr DRIP, annual income (after tax)
$532.87/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $2,713.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYNH + EQR for your $10,000?

SYNH: 50%EQR: 50%
100% EQR50/50100% SYNH
Portfolio after 10yr
$33.8K
Annual income
$2,223.25/yr
Blended yield
6.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SYNH
Analyst Ratings
12
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$72.00
+67.5% upside vs current
Range: $25.00 — $105.00
Altman Z
1.4
Piotroski
7/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYNH buys
0
EQR buys
0
No recent congressional trades found for SYNH or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNHEQR
Forward yield4.65%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$27.1K$40.5K
Annual income after 10y$626.90$3,819.61
Total dividends collected$5.5K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$72.00$70.35

Year-by-year: SYNH vs EQR ($10,000, DRIP)

YearSYNH PortfolioSYNH Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,165$465.33$11,248$547.57$83.00EQR
2$12,432$485.57$12,701$666.53$269.00EQR
3$13,808$505.31$14,405$814.59$597.00EQR
4$15,299$524.50$16,413$999.84$1.1KEQR
5$16,913$543.12$18,795$1,232.92$1.9KEQR
6$18,658$561.14$21,639$1,527.95$3.0KEQR
7$20,543$578.54$25,057$1,903.80$4.5KEQR
8$22,576$595.30$29,197$2,385.87$6.6KEQR
9$24,768$611.43$34,250$3,008.70$9.5KEQR
10$27,129$626.90$40,467$3,819.61$13.3KEQR

SYNH vs EQR: Complete Analysis 2026

SYNHStock

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Full SYNH Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SYNH vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYNH vs SCHDSYNH vs JEPISYNH vs OSYNH vs KOSYNH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.